Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador

La enfermedad pulmonar obstructiva crónica (EPOC) es una enfermedad común, prevenible y tratable, con alta carga de morbimortalidad y gran uso de recursos en salud, que se caracteriza por síntomas respiratorios persistentes y limitaciónen el tracto respiratorio secundario. Se reportó como la cuarta...

Full description

Autores:
Gomez Contreras, María Camila
Sguerra Bergsneider, María Paula
Estupiñan Dueñas, Lizeth Idaly
Bernal Alarcón, Diego Nicolás
Castañeda Saavedra, Stefania de los Ángeles
Albarracin Ruiz, Maria Jose
Cano Rosales, Diana Jimena
Tipo de recurso:
http://purl.org/coar/resource_type/c_f744
Fecha de publicación:
2018
Institución:
Universidad Autónoma de Bucaramanga - UNAB
Repositorio:
Repositorio UNAB
Idioma:
spa
OAI Identifier:
oai:repository.unab.edu.co:20.500.12749/21674
Acceso en línea:
http://hdl.handle.net/20.500.12749/21674
Palabra clave:
Health sciences
Clinical investigations
Internal medicine
Pneumology
Investigation
COPD
Oxidative stress
Serum zinc levels
Exacerbator phenotype
Ciencias de la salud
Investigaciones clínicas
Medicina interna
Neumología
Investigación
EPOC
Estrés oxidativo
Niveles de zinc sérico
Fenotipo exacerbador
Rights
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id UNAB2_7becff8dc9dabab4e342eedb014e2221
oai_identifier_str oai:repository.unab.edu.co:20.500.12749/21674
network_acronym_str UNAB2
network_name_str Repositorio UNAB
repository_id_str
dc.title.spa.fl_str_mv Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador
dc.title.translated.spa.fl_str_mv Zinc Levels in Patients With COPD Phenotype exacerbator
title Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador
spellingShingle Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador
Health sciences
Clinical investigations
Internal medicine
Pneumology
Investigation
COPD
Oxidative stress
Serum zinc levels
Exacerbator phenotype
Ciencias de la salud
Investigaciones clínicas
Medicina interna
Neumología
Investigación
EPOC
Estrés oxidativo
Niveles de zinc sérico
Fenotipo exacerbador
title_short Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador
title_full Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador
title_fullStr Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador
title_full_unstemmed Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador
title_sort Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador
dc.creator.fl_str_mv Gomez Contreras, María Camila
Sguerra Bergsneider, María Paula
Estupiñan Dueñas, Lizeth Idaly
Bernal Alarcón, Diego Nicolás
Castañeda Saavedra, Stefania de los Ángeles
Albarracin Ruiz, Maria Jose
Cano Rosales, Diana Jimena
dc.contributor.author.none.fl_str_mv Gomez Contreras, María Camila
Sguerra Bergsneider, María Paula
Estupiñan Dueñas, Lizeth Idaly
Bernal Alarcón, Diego Nicolás
Castañeda Saavedra, Stefania de los Ángeles
Albarracin Ruiz, Maria Jose
Cano Rosales, Diana Jimena
dc.contributor.cvlac.spa.fl_str_mv Gomez Contreras, María Camila [0001664780]
Albarracín Ruiz, María José [0001649451]
Cano Rosales, Diana Jimena [0000947237]
dc.contributor.orcid.spa.fl_str_mv Gomez Contreras, María Camila [0000-0003-0542-4622]
Bernal Alarcón, Diego Nicolás [0000-0003-2072-9731]
Cano Rosales, Diana Jimena [0000-0002-7090-5142]
dc.contributor.researchgroup.spa.fl_str_mv Semilleros de Investigación UNAB
dc.subject.keywords.spa.fl_str_mv Health sciences
Clinical investigations
Internal medicine
Pneumology
Investigation
COPD
Oxidative stress
Serum zinc levels
Exacerbator phenotype
topic Health sciences
Clinical investigations
Internal medicine
Pneumology
Investigation
COPD
Oxidative stress
Serum zinc levels
Exacerbator phenotype
Ciencias de la salud
Investigaciones clínicas
Medicina interna
Neumología
Investigación
EPOC
Estrés oxidativo
Niveles de zinc sérico
Fenotipo exacerbador
dc.subject.lemb.spa.fl_str_mv Ciencias de la salud
Investigaciones clínicas
Medicina interna
Neumología
Investigación
dc.subject.proposal.spa.fl_str_mv EPOC
Estrés oxidativo
Niveles de zinc sérico
Fenotipo exacerbador
description La enfermedad pulmonar obstructiva crónica (EPOC) es una enfermedad común, prevenible y tratable, con alta carga de morbimortalidad y gran uso de recursos en salud, que se caracteriza por síntomas respiratorios persistentes y limitaciónen el tracto respiratorio secundario. Se reportó como la cuarta causa de muerte en el mundo en el año 2010 y en Colombia como la quinta causa de mortalidad prematura, contribuyendo en gran parte a años de vida perdidos por enfermedad. En pacientes con EPOC, la respuesta inflamatoria generada por mediadores proinflamatorios que infiltran el epitelio aéreo promueven estrés oxidativo que ocasiona el compromiso de la vía aérea cuyas manifestaciones clínicas son el broncoespasmo, edema y persistencia de la inflamación local. El estrés oxidativo generado es un factor determinante en la progresión de la enfermedad, interviene crónicamente en la inflamación bronquial y parenquimatosa pulmonar; se han descrito intervenciones con el fin de disminuirlo como el suplemento de antioxidantes sintéticos o dietéticos y la modificación de factores ambientales que promueven la oxidación como el Zinc. Existe controversia sobre la influencia de los niveles de zinc en pacientes con enfermedades respiratorias. La investigación se ha centrado en pacientes asmáticos y se ha estudiado en menor proporción en los pacientes con EPOC, en los cuales la evidencia sobre el zinc es mínima y no hay un consenso que separe el manejo dietario con suplementos como el zinc en los pacientes con fenotipo exacerbador frecuente versus el fenotipo no exacerbador. A través de este estudio, se propone medir marcadores inflamatorios, se propone medir marcadores inflamatorios de estrés oxidativo y de sustancias relacionadas con la inflamación en los pacientes con EPOC, para determinar el impacto de estos niveles séricos en las exacerbaciones en nuestra población a estudio.
publishDate 2018
dc.date.issued.none.fl_str_mv 2018-11
dc.date.accessioned.none.fl_str_mv 2023-09-05T19:32:43Z
dc.date.available.none.fl_str_mv 2023-09-05T19:32:43Z
dc.type.eng.fl_str_mv Conference
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/conferenceProceedings
dc.type.local.spa.fl_str_mv Memoria de eventos
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_f744
dc.type.hasversion.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.redcol.none.fl_str_mv http://purl.org/redcol/resource_type/EC_AC
format http://purl.org/coar/resource_type/c_f744
status_str acceptedVersion
dc.identifier.issn.spa.fl_str_mv ISSN 2344-7079
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12749/21674
dc.identifier.instname.spa.fl_str_mv instname:Universidad Autónoma de Bucaramanga - UNAB
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional UNAB
dc.identifier.repourl.spa.fl_str_mv repourl:https://repository.unab.edu.co
identifier_str_mv ISSN 2344-7079
instname:Universidad Autónoma de Bucaramanga - UNAB
reponame:Repositorio Institucional UNAB
repourl:https://repository.unab.edu.co
url http://hdl.handle.net/20.500.12749/21674
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.ispartofseries.spa.fl_str_mv Generación Creativa : Encuentro de Semilleros de Investigación UNAB
dc.relation.uri.none.fl_str_mv http://hdl.handle.net/20.500.12749/14242
dc.relation.references.spa.fl_str_mv 1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar;195(5):557–82.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012 Dec;380(9859):2095–128.
3. WHO | The global burden. WHO [Internet]. 2010 [cited 2017 Sep 21]; Available from: http://who.int/substance_abuse/facts/global_burden/en/
4. Partridge MR, Miravitlles M, Stahl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J [Internet]. 2010 Jul 1 [cited 2017 Sep 21];36(1):96–104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19897551
5. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J [Internet]. 2009 May 1 [cited 2017 Sep 21];33(5):1165–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19407051
6. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet [Internet]. 2007 Sep 1 [cited 2017 Sep 21];370(9589):797–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17765529
7. Rerksuppaphol S, Rerksuppaphol L. Zinc Supplementation in Children with Asthma Exacerbation. Pediatr Rep [Internet]. 2016 Nov 17 [cited 2017 Sep 21];8(4):6685. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28058103
8. Riccioni G, D’Orazio N. The role of selenium, zinc and antioxidant vitamin supplementation in the treatment of bronchial asthma: adjuvant therapy or not? Expert Opin Investig Drugs [Internet]. 2005 Sep 22 [cited 2017 Sep 21];14(9):1145–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16144498
9. Guo C-H, Liu P-J, Lin K-P, Chen P-C. Nutritional supplement therapy improves oxidative stress, immune response, pulmonary function, and quality of life in allergic asthma patients: an open-label pilot study. Altern Med Rev [Internet]. 2012 Mar [cited 2017 Sep 19];17(1):42–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22502622
10. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet [Internet]. 2012 Dec 15 [cited 2017 Sep 14];380(9859):2197–223. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23245608
11. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet [Internet]. 2004 Aug [cited 2017 Sep 14];364(9434):613– 20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15313363
12. Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev [Internet]. 2009 [cited 2017 Sep 13];18(114). Available from: http://err.ersjournals.com/content/18/114/213#T2
13. Menezes AMB, Perez-Padilla R, Jardim JRB, Muiño A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet (London, England). 2005 Nov;366(9500):1875–81.
14. Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343–9.
15. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2010 Sep 16 [cited 2017 Sep 14];363(12):1128– 38. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0909883
16. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study. Respir Res [Internet]. 2009 Dec 30 [cited 2017 Sep 14];10(1):59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19566934
17. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet [Internet]. 2009 Oct 3 [cited 2017 Sep 14];374(9696):1171–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19716598
18. Soler-Cataluna JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax [Internet]. 2005 Nov 1 [cited 2017 Sep 14];60(11):925–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16055622
19. Pauwels RA, Löfdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking. N Engl J Med. 1999 Jun;340(25):1948–53.
20. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (London, England). 1999 May;353(9167):1819–23.
21. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2008 Oct 9 [cited 2017 Sep 12];359(15):1543–54. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0805800
22. O’Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6).
23. O’Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, et al. Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest. 2006 Sep;130(3):647–56.
24. Zalewski PD, Truong-Tran AQ, Grosser D, Jayaram L, Murgia C, Ruffin RE. Zinc metabolism in airway epithelium and airway inflammation: Basic mechanisms and clinical targets. A review. Pharmacol Ther. 2005;105(2):127–49.
25. Zalewski PD. Zinc metabolism in the airway: basic mechanisms and drug targets. Curr Opin Pharmacol. 2006;6(3):237–43.
26. Daga MK, Chhabra R, Sharma B, Mishra TK. Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. J Biosci [Internet]. 2003 Feb [cited 2017 Sep 19];28(1):7–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12682418
27. Kondo T, Tagami S, Yoshioka A, Nishimura M, Kawakami Y. Current smoking of elderly men reduces antioxidants in alveolar macrophages. Am J Respir Crit Care Med [Internet]. 1994 Jan [cited 2017 Sep 19];149(1):178–82. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm.149.1.8 111579
28. Di Toro R, Galdo Capotorti G, Gialanella G, Miraglia del Giudice M, Moro R, Perrone L. Zinc and copper status of allergic children. Acta Paediatr Scand [Internet]. 1987 Jul [cited 2017 Sep 19];76(4):612–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3630679
29. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids [Internet]. 2000 Sep [cited 2017 Sep 19];35(9):967– 74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11026617
30. el-Kholy MS, Gas Allah MA, el-Shimi S, el-Baz F, elTayeb H, Abdel-Hamid MS. Zinc and copper status in children with bronchial asthma and atopic dermatitis. J Egypt Public Health Assoc [Internet]. 1990 [cited 2017 Sep 19];65(5–6):657–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2134100
31. Kadrabová J, Mad’aric A, Podivínsky F, Gazdík F, Ginter F. Plasma zinc, copper and copper/zinc ratio in intrinsic asthma. J Trace Elem Med Biol [Internet]. 1996 Apr [cited 2017 Sep 19];10(1):50–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8793823
32. Kirkil G, Hamdi Muz M, Seçkin D, Sahin K, Küçük O. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease. Respir Med [Internet]. 2008;102(6):840–4. Available from: www.pubmed.gov
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.local.spa.fl_str_mv Abierto (Texto Completo)
dc.rights.creativecommons.*.fl_str_mv Atribución-NoComercial-SinDerivadas 2.5 Colombia
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Abierto (Texto Completo)
Atribución-NoComercial-SinDerivadas 2.5 Colombia
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.coverage.spatial.spa.fl_str_mv Bucaramanga (Santander, Colombia)
dc.coverage.temporal.spa.fl_str_mv 2018
dc.coverage.campus.spa.fl_str_mv UNAB Campus Bucaramanga
dc.publisher.grantor.spa.fl_str_mv Universidad Autónoma de Bucaramanga UNAB
dc.publisher.faculty.none.fl_str_mv Facultad Ciencias de la Salud
dc.publisher.program.none.fl_str_mv Pregrado Medicina
dc.publisher.deparment.spa.fl_str_mv Sistema de Investigación SIUNAB
dc.source.spa.fl_str_mv Gomez, M. C., et al. (2018). Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador. Recuperado de: http://hdl.handle.net/20.500.12749/21674
institution Universidad Autónoma de Bucaramanga - UNAB
bitstream.url.fl_str_mv https://repository.unab.edu.co/bitstream/20.500.12749/21674/1/2018_Articulo_Gomez_Contreras_Maria_Camila.pdf
https://repository.unab.edu.co/bitstream/20.500.12749/21674/2/license.txt
https://repository.unab.edu.co/bitstream/20.500.12749/21674/3/2018_Articulo_Gomez_Contreras_Maria_Camila.pdf.jpg
bitstream.checksum.fl_str_mv 179c9a625655457f8e495cee196ce1ce
3755c0cfdb77e29f2b9125d7a45dd316
b019cadc0a42ba71675215c620efa63b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional | Universidad Autónoma de Bucaramanga - UNAB
repository.mail.fl_str_mv repositorio@unab.edu.co
_version_ 1814278428144173056
spelling Gomez Contreras, María Camila8bd36573-0c58-404b-807e-cae9dcdcf5edSguerra Bergsneider, María Paula4a508297-5186-492e-bb7b-4776b5044f7cEstupiñan Dueñas, Lizeth Idalydab7f325-97cc-43f3-b1ba-44359860793dBernal Alarcón, Diego Nicoláse041aab9-de85-4d37-bb9b-cadd0fe7d134Castañeda Saavedra, Stefania de los Ángeles79856896-616f-4ad0-b45d-43c6e61affcaAlbarracin Ruiz, Maria Jose1c1b184b-eeac-4b3a-8144-5c45479b0be4Cano Rosales, Diana Jimena409119ff-bff2-47b1-af20-7e55308c245bGomez Contreras, María Camila [0001664780]Albarracín Ruiz, María José [0001649451]Cano Rosales, Diana Jimena [0000947237]Gomez Contreras, María Camila [0000-0003-0542-4622]Bernal Alarcón, Diego Nicolás [0000-0003-2072-9731]Cano Rosales, Diana Jimena [0000-0002-7090-5142]Semilleros de Investigación UNABBucaramanga (Santander, Colombia)2018UNAB Campus Bucaramanga2023-09-05T19:32:43Z2023-09-05T19:32:43Z2018-11ISSN 2344-7079http://hdl.handle.net/20.500.12749/21674instname:Universidad Autónoma de Bucaramanga - UNABreponame:Repositorio Institucional UNABrepourl:https://repository.unab.edu.coLa enfermedad pulmonar obstructiva crónica (EPOC) es una enfermedad común, prevenible y tratable, con alta carga de morbimortalidad y gran uso de recursos en salud, que se caracteriza por síntomas respiratorios persistentes y limitaciónen el tracto respiratorio secundario. Se reportó como la cuarta causa de muerte en el mundo en el año 2010 y en Colombia como la quinta causa de mortalidad prematura, contribuyendo en gran parte a años de vida perdidos por enfermedad. En pacientes con EPOC, la respuesta inflamatoria generada por mediadores proinflamatorios que infiltran el epitelio aéreo promueven estrés oxidativo que ocasiona el compromiso de la vía aérea cuyas manifestaciones clínicas son el broncoespasmo, edema y persistencia de la inflamación local. El estrés oxidativo generado es un factor determinante en la progresión de la enfermedad, interviene crónicamente en la inflamación bronquial y parenquimatosa pulmonar; se han descrito intervenciones con el fin de disminuirlo como el suplemento de antioxidantes sintéticos o dietéticos y la modificación de factores ambientales que promueven la oxidación como el Zinc. Existe controversia sobre la influencia de los niveles de zinc en pacientes con enfermedades respiratorias. La investigación se ha centrado en pacientes asmáticos y se ha estudiado en menor proporción en los pacientes con EPOC, en los cuales la evidencia sobre el zinc es mínima y no hay un consenso que separe el manejo dietario con suplementos como el zinc en los pacientes con fenotipo exacerbador frecuente versus el fenotipo no exacerbador. A través de este estudio, se propone medir marcadores inflamatorios, se propone medir marcadores inflamatorios de estrés oxidativo y de sustancias relacionadas con la inflamación en los pacientes con EPOC, para determinar el impacto de estos niveles séricos en las exacerbaciones en nuestra población a estudio.Chronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable disease. COPD has a high rate of morbidity and mortality and it also, implies a high use of health resources. COPD is characterised by persistent respiratory symptoms and limitation of the secondary respiratory tract. It was eported as the fourth highest cause of prematue mortality in the world, and fifth locally, in Colombia. Which is reflected in contribution to the huge amount of loss life years because of a disease. In Patients with COPD, the inflammatory response is generated by pro inflammatory mediators which cross the airway epithelium promoting oxidative stress, which further compromises the airway; Its clinic hallmarks are bronchospasm, edema, and persistent local inflammation. Generated oxidative stressis a core factor in the disease evolution, it chronically intervenes in the bronchial and pulmonary parenchymal inflammation. It has been described interventions with the purpose of diminish it as a supplement of synthetic or dietetic antioxidants and the modification of environmental factors which promote the oxidation, such as Zinc. A controversy exists about the Zinc levels influence on patients with respiratory diseases. The research has focused on asthmatic patients, leaving COPD patients in fewer proportion, where is possessed minimal evidence about Zinc influence. There is also no consensus which differentiates the dietary management of supplements such as Zinc, in patients with exacerbator phenotype against with non-exacerbator phenotype Calculating markers of inflammation is proposed through this study, specifically those related with oxidative stress and pro inflammation substances in COPD patients. In order to determine the relative impact of these serum levels in the exacerbations of our designated study population.Modalidad Presencialapplication/pdfspaGeneración Creativa : Encuentro de Semilleros de Investigación UNABhttp://hdl.handle.net/20.500.12749/142421. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar;195(5):557–82.2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012 Dec;380(9859):2095–128.3. WHO | The global burden. WHO [Internet]. 2010 [cited 2017 Sep 21]; Available from: http://who.int/substance_abuse/facts/global_burden/en/4. Partridge MR, Miravitlles M, Stahl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J [Internet]. 2010 Jul 1 [cited 2017 Sep 21];36(1):96–104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/198975515. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J [Internet]. 2009 May 1 [cited 2017 Sep 21];33(5):1165–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/194070516. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet [Internet]. 2007 Sep 1 [cited 2017 Sep 21];370(9589):797–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/177655297. Rerksuppaphol S, Rerksuppaphol L. Zinc Supplementation in Children with Asthma Exacerbation. Pediatr Rep [Internet]. 2016 Nov 17 [cited 2017 Sep 21];8(4):6685. Available from: http://www.ncbi.nlm.nih.gov/pubmed/280581038. Riccioni G, D’Orazio N. The role of selenium, zinc and antioxidant vitamin supplementation in the treatment of bronchial asthma: adjuvant therapy or not? Expert Opin Investig Drugs [Internet]. 2005 Sep 22 [cited 2017 Sep 21];14(9):1145–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/161444989. Guo C-H, Liu P-J, Lin K-P, Chen P-C. Nutritional supplement therapy improves oxidative stress, immune response, pulmonary function, and quality of life in allergic asthma patients: an open-label pilot study. Altern Med Rev [Internet]. 2012 Mar [cited 2017 Sep 19];17(1):42–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2250262210. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet [Internet]. 2012 Dec 15 [cited 2017 Sep 14];380(9859):2197–223. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2324560811. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet [Internet]. 2004 Aug [cited 2017 Sep 14];364(9434):613– 20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1531336312. Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev [Internet]. 2009 [cited 2017 Sep 13];18(114). Available from: http://err.ersjournals.com/content/18/114/213#T213. Menezes AMB, Perez-Padilla R, Jardim JRB, Muiño A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet (London, England). 2005 Nov;366(9500):1875–81.14. Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343–9.15. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2010 Sep 16 [cited 2017 Sep 14];363(12):1128– 38. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa090988316. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study. Respir Res [Internet]. 2009 Dec 30 [cited 2017 Sep 14];10(1):59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1956693417. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet [Internet]. 2009 Oct 3 [cited 2017 Sep 14];374(9696):1171–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1971659818. Soler-Cataluna JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax [Internet]. 2005 Nov 1 [cited 2017 Sep 14];60(11):925–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1605562219. Pauwels RA, Löfdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking. N Engl J Med. 1999 Jun;340(25):1948–53.20. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (London, England). 1999 May;353(9167):1819–23.21. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2008 Oct 9 [cited 2017 Sep 12];359(15):1543–54. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa080580022. O’Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6).23. O’Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, et al. Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest. 2006 Sep;130(3):647–56.24. Zalewski PD, Truong-Tran AQ, Grosser D, Jayaram L, Murgia C, Ruffin RE. Zinc metabolism in airway epithelium and airway inflammation: Basic mechanisms and clinical targets. A review. Pharmacol Ther. 2005;105(2):127–49.25. Zalewski PD. Zinc metabolism in the airway: basic mechanisms and drug targets. Curr Opin Pharmacol. 2006;6(3):237–43.26. Daga MK, Chhabra R, Sharma B, Mishra TK. Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. J Biosci [Internet]. 2003 Feb [cited 2017 Sep 19];28(1):7–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1268241827. Kondo T, Tagami S, Yoshioka A, Nishimura M, Kawakami Y. Current smoking of elderly men reduces antioxidants in alveolar macrophages. Am J Respir Crit Care Med [Internet]. 1994 Jan [cited 2017 Sep 19];149(1):178–82. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm.149.1.8 11157928. Di Toro R, Galdo Capotorti G, Gialanella G, Miraglia del Giudice M, Moro R, Perrone L. Zinc and copper status of allergic children. Acta Paediatr Scand [Internet]. 1987 Jul [cited 2017 Sep 19];76(4):612–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/363067929. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids [Internet]. 2000 Sep [cited 2017 Sep 19];35(9):967– 74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1102661730. el-Kholy MS, Gas Allah MA, el-Shimi S, el-Baz F, elTayeb H, Abdel-Hamid MS. Zinc and copper status in children with bronchial asthma and atopic dermatitis. J Egypt Public Health Assoc [Internet]. 1990 [cited 2017 Sep 19];65(5–6):657–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/213410031. Kadrabová J, Mad’aric A, Podivínsky F, Gazdík F, Ginter F. Plasma zinc, copper and copper/zinc ratio in intrinsic asthma. J Trace Elem Med Biol [Internet]. 1996 Apr [cited 2017 Sep 19];10(1):50–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/879382332. Kirkil G, Hamdi Muz M, Seçkin D, Sahin K, Küçük O. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease. Respir Med [Internet]. 2008;102(6):840–4. Available from: www.pubmed.govhttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Abierto (Texto Completo)Atribución-NoComercial-SinDerivadas 2.5 Colombiahttp://purl.org/coar/access_right/c_abf2Gomez, M. C., et al. (2018). Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador. Recuperado de: http://hdl.handle.net/20.500.12749/21674Niveles De Zinc En Pacientes Con Epoc Fenotipo ExacerbadorZinc Levels in Patients With COPD Phenotype exacerbatorConferenceinfo:eu-repo/semantics/conferenceProceedingsMemoria de eventoshttp://purl.org/coar/resource_type/c_f744info:eu-repo/semantics/acceptedVersionhttp://purl.org/redcol/resource_type/EC_ACUniversidad Autónoma de Bucaramanga UNABFacultad Ciencias de la SaludPregrado MedicinaSistema de Investigación SIUNABHealth sciencesClinical investigationsInternal medicinePneumologyInvestigationCOPDOxidative stressSerum zinc levelsExacerbator phenotypeCiencias de la saludInvestigaciones clínicasMedicina internaNeumologíaInvestigaciónEPOCEstrés oxidativoNiveles de zinc séricoFenotipo exacerbadorORIGINAL2018_Articulo_Gomez_Contreras_Maria_Camila.pdf2018_Articulo_Gomez_Contreras_Maria_Camila.pdfArtículoapplication/pdf274628https://repository.unab.edu.co/bitstream/20.500.12749/21674/1/2018_Articulo_Gomez_Contreras_Maria_Camila.pdf179c9a625655457f8e495cee196ce1ceMD51open accessLICENSElicense.txtlicense.txttext/plain; charset=utf-8829https://repository.unab.edu.co/bitstream/20.500.12749/21674/2/license.txt3755c0cfdb77e29f2b9125d7a45dd316MD52open accessTHUMBNAIL2018_Articulo_Gomez_Contreras_Maria_Camila.pdf.jpg2018_Articulo_Gomez_Contreras_Maria_Camila.pdf.jpgIM Thumbnailimage/jpeg10137https://repository.unab.edu.co/bitstream/20.500.12749/21674/3/2018_Articulo_Gomez_Contreras_Maria_Camila.pdf.jpgb019cadc0a42ba71675215c620efa63bMD53open access20.500.12749/21674oai:repository.unab.edu.co:20.500.12749/216742023-09-05 22:01:49.716open accessRepositorio Institucional | Universidad Autónoma de Bucaramanga - UNABrepositorio@unab.edu.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

Publicaciones similares